Alphamab and Pfizer Initiate P-II Trial Evaluating KN046 + Inlyta (axitinib) as a 1L Treatment of Non-Small Cell Lung Cancer

Shots:

• The P-II trial will evaluate the efficacy, safety, and tolerability of KN046 + Pfizer’s Inlyta (axitinib) as a 1L treatment of NSCLC. The 1EPs of the study are ORR
• The P-II trial of KN046 for advanced NSCLC has demonstrated superior tolerability, safety, as well as PFS and OS. Following the results, the companies have initiated P-III ENREACH-LUNG-01 trial to explore new 1L standard therapies for lung cancer
• In Mar’2020, the companies collaborated to evaluate KN026 in + Ibrance (palbociclib) and have received NMPA’s IND approval in Dec’2020

Click here to­ read full press release/ article | Ref: PRN Asia | Image: Pfizer